Sources of funding
Introduction
Globally, approximately 1.1m preterm (<37 weeks gestation) infants die each year, with the infant mortality rate for preterm infants at least three times that for term infants 1 . One condition mainly affecting preterm or low birth weight (<2,500g) infants is necrotizing enterocolitis (NEC) 2 . The incidence of NEC in developed countries is up to 13% amongst low birth weight infants and/or those born before 33 weeks 2 . NEC is usually treated medically with bowel rest and systemic antibiotics but more severe cases are treated surgically via peritoneal drainage and laparotomy 2, 3 . A systematic review suggested an overall mortality rate of around 20% 4 , with up to five-fold higher mortality amongst those requiring surgery 5 .
Many agree that breast milk is a natural prophylactic for NEC [6] [7] [8] and mother's own breast milk is clearly the optimal choice for all infants for this, plus many other reasons 9 .
However, mothers with preterm babies may not be able to produce enough milk, may be too ill to breastfeed or may die in childbirth 10 . In this situation, the World Health Organization and others recommend using donor human breast milk (donor milk) which confers a number of advantages over the alternative of formula milk 9, [11] [12] [13] . A recent systematic review 7 reports that donor milk reduces the risk of NEC by almost two-thirds compared with formula. However, not all preterm babies who do not receive their mother's own milk receive donor milk instead 14, 15 . Donor milk is more expensive than formula and while it confers various health benefits, it is not known whether its use is cost-effective [16] [17] [18] .
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We therefore undertook a systematic review to answer the following questions:
1. What is the cost of donor milk?
2. What is the initial cost to the health service of treating medical and surgical NEC?
3. Is exclusive donor milk feeding cost-saving and/or cost-effective compared to exclusive formula milk feeding when considering its impact on the short-term cost and health outcomes associated with NEC?
Materials and Methods
The protocol was registered on PROSPERO (reference number CRD42016042581). Short-term is defined as the time from birth to initial post-natal discharge. Costs data had to be 'verifiable' i.e. specified the data source. We sought costs data but included charges (to the patient or other payer) if costs were not reported.
 Study design: Any study reporting costs of donor milk and/or NEC, or any form of economic evaluation. Protocols, opinion pieces/editorials and abstracts were excluded.
 Language and date: Due to resource constraints, only English language studies were included. We only sought studies published since January 1996 to recognise expected changes in cost structures over time.
 Publication status: Grey literature was sought.
Search methods
We carried out two search strategies; the first to identify costs of donor milk and the second to identify costs of treating NEC. Both search strategies were also used to identify studies including any form of economic evaluation. 
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The full search strategy can be found in Supplementary File 1. For both searches, the references of any relevant reviews or studies meeting the eligibility criteria were checked to identify any further studies/sources.
Study selection
The search results were de-duplicated using EndNote v7. Both authors independently screened all of the titles and abstracts against the eligibility criteria. All studies that either author thought should be included were added to a full text list. These studies were then read independently in full and each author made a decision on whether or not each study should be included. Discrepancies were discussed until agreement was reached.
Data collection process and data items 
Results

Study selection
The numbers of studies screened, assessed for eligibility and included and excluded in the review can be seen in Figure 1 .
Cost of donor milk
Seven estimates of the cost of donor milk were reported across six studies 4, [21] [22] [23] [24] [25] [26] . The cost per 100ml donor milk in each study can be seen in Table 1 . Only one study reported the cost of production 4 , which at $51/100ml was actually considerably larger than any of the studies reporting charges (to the health service). The authors noted that improvements in how the milk banking service was organised could reduce this cost to a more comparable $21/100ml .
Economic evaluation of donor milk compared with formula milk
We initially identified three economic evaluations 4, 32, 39 . While none of these met all of our inclusion criteria, it is important to consider why and to discuss other limitations of the two studies that claimed to provide economic evaluations of the use of donor milk.
Wight 32 presented a return on investment analysis for the use of donor milk for very low birth weight infants (<1,500g). Three outcomes were considered: NEC, sepsis and overall length of stay (for any reason related to the use of human milk rather than formula). The analysis was based on local treatment costs of NEC and sepsis and daily "hotel" costs, but excluding physician fees. The unit cost of donor milk was provided by the local milk bank. Effectiveness data were taken from a single, non-randomised study comparing the use of fortified mother's own milk (not donor milk) with formula 40 , which is problematic as donor milk is unlikely to be as effective as mother's own milk 4 (although for ethical reasons there are no "head-to-head" trials of donor milk vs. mother's own milk). In the economic analysis, infants could be fed with donor milk for either one or two months, although no rationale for these durations was provided and effectiveness was assumed to be equal regardless of duration of use. The method of calculating total milk requirements (2,000ml for one month or 7,100ml for two months) was not described. Formula milk was assumed to be free of charge. The year of costing was not specified and no sensitivity analysis was performed. . This is problematic because differences in study contexts reduce comparability and a failure to consider that the 10.1% risk for all infants is a weighted average of the risks for human and nonhuman milk and not a sum of the risks in these two feeding conditions.
14 The main intervention being evaluated in Renfrew et al.'s economic evaluation 4 was the provision of a lactation consultant to help mothers breastfeed their own infants. The use of donor milk was considered in a secondary analysis, as an adjunct to mother's own milk, so the comparison was not between exclusive use of donor milk and exclusive use of formula.
Discussion
We found six studies including verifiable costs or charges of donor milk. Four of these were conducted in the US and the mean cost of donor milk across these studies was approximately $14 per 100ml. Based on existing estimates of donor milk use 20, 21 , this would equate to costs of just under $300 per very low birth weight infant and of around $1,500 for an infant fed entirely on donor milk. We found 17 studies including initial costs to the health service/charges for the treatment of NEC; however there was insufficient comparability between the estimates provided to enable quantitative synthesis. Many studies did not even report what cost components were or were not included in their estimates. In particular, studies reporting the cost of donor milk did not include the fixed costs of setting up a milk bank (meaning the costs reported here are underestimates) or which specific tests on donors and their milk were undertaken. In addition, studies only reporting charges are particularly difficult to synthesise as cost to charge ratios vary between hospitals. Even within primary studies evaluating the cost of treating NEC, there was considerable variation between costs for individual infants suggesting that costs are also affected by a range of other factors/comorbidities. Future costing studies should clearly specify which costs are included, if possible using a "bottom-up" approach to costing.
Estimates of (excess) length of stay are easier to compare than NEC treatment costs and enable local bed-day costs to be applied by others wanting to estimate the financial impact of NEC on their own institution. suggested that exclusive donor milk could be cost-saving and would therefore dominate the use of formula milk for preterm infants. However neither study is of sufficient methodological quality to provide convincing evidence of the cost-effectiveness of donor milk. Our protocol did not include the use of the results from our review of costs in a "back of the envelope" economic evaluation which could be subject to similar concerns regarding methodological quality. Therefore, while we believe it is likely that the use of donor milk would be at least cost-effective, and possibly also cost-saving compared with formula milk, we agree with others [16] [17] [18] that a full economic evaluation is warranted.
Such an evaluation could consider both the use of exclusive donor milk vs. exclusive formula milk, different durations of donor milk feeding (with differential effectiveness) and/or the use of donor milk as a complement or 'top-up' to mother's own milk while breastfeeding is being established. It should include all the major short and long-term health (and associated cost) consequences related to the use of donor rather than formula milk (not just NEC) and potentially issues related to the acceptability of donor milk to parents 18, 43, 44 . While our results provide a starting point, any economic evaluation will need to clearly justify the costs of donor milk and NEC used as parameter inputs and, given the wide range of costs in the studies included in this review, it should include a range of sensitivity analyses to determine the robustness of the results to different costs of donor milk and NEC treatment. It may also be helpful to contact milk banks directly for costs data as part of an economic evaluation.
Our review is not without its limitations. On the cost of donor milk, we did not compare donor milk practices and organisation, health systems or breastfeeding cultures in each of the countries in which the included studies were undertaken and it may be that the large variation in costs is partially explained by such differences, which may even exist within countries. In the UK, for example, England tends to be served by local milk banks (N=14 nationwide) while one bank covers the whole of Scotland 45 . On the cost of NEC, we did not specifically search for studies assessing length of stay that did not also include costs so we may have missed some primary studies. On economic evaluations, our inclusion criteria meant that only studies comparing the use of exclusive donor vs.
formula milk were included. The use of exclusive donor milk is rare in practice (but may occur, for example, where a mother dies in childbirth or is HIV positive and cannot safely breastfeed). This restriction was intended to ensure a consistent comparator so that we could synthesis results across studies but may mean we have excluded studies that would have provided an insight into the cost-effectiveness of donor milk. We did not compare donor milk with mother's own milk because the latter would clearly dominate in an economic evaluation, being both cheaper and at least as effective. Using the idea of extended dominance, if exclusive donor milk was found to be cost-effective compared with formula, then using donor milk as an adjunct to mother's own milk would be even more so. This is because the cost of donor milk would be reduced by over 70% and health outcomes would be at least as good.
We focused on the incidence and short-term costs of NEC as the only outcome associated with the use of donor milk. It may also be the case that donor milk reduces the severity of NEC, although to claim this we currently need to generalise from the results of a study using mother's own milk 46 . There are many other potential benefits of human milk such as reduced neurodevelopmental complications, neonatal infections and improved cardiovascular health [47] [48] [49] [50] , as well as potential risks if safety standards are not maintained 17 and a possible link with slower weight gain 7 . These additional outcomes would have implications for both the costs and health outcomes associated with the use of donor milk. Spill-over effects should also be considered. One concern is that the provision of donor milk 'crowds out' mother's own milk and this reduces breastfeeding rates. However a recent systematic review suggests that this is not the case in practice 51 . The studies identified were all carried out in developed countries, which may limit the international generalisability of the findings and publication bias may also be a problem, particularly for any economic evaluations that did not find positive evidence of the use of donor milk. While we used Google Scholar in an attempt to find grey literature we were unable to evaluate the extent of publication bias. We may also have missed studies published in languages other than English. In an attempt to maximise the credibility of our findings, we excluded studies where costs could not be 'verified' i.e. traced back to their original source. However no other quality appraisal of costing studies was undertaken. We also excluded a study where donor milk was
purchased on the open market rather than from an official milk bank 52 .
Conclusion
It is likely that the use of donor milk is cost-effective. To strengthen the evidence base there is a need for a comprehensive economic evaluation of the use of donor milk, focusing on providing evidence in contexts where the use of donor milk is not currently standard practice. Such work should carefully describe how the costs of donor milk and of its implications for healthcare have been generated, given the variability in the estimates we have identified between contexts, and, for some outcomes, also within contexts. 
